BERNS PAUL L
10% Owner; Director, 10% Owner; Director, Title: Chief Executive Officer and Chairman of the Board · 4 filings · Latest: Jun 22, 2026
Kardigan, Inc.
Lyell Immunopharma, Inc.
Neumora Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
KARD | BERNS PAUL L | Director, 10% Owner | Jun 22, 2026 | Purchase | $16.00 | 1,250,000 | $20.0M | 15,042,035 | |
LYEL | BERNS PAUL L | 10% Owner | Mar 6, 2026 | Purchase | $25.61 | 488,090 | $12.5M | 1,426,528 | |
NMRA | BERNS PAUL L | Director, Title: Chief Executive Officer and Chairman of the Board | Feb 17, 2026 | Sale | $3.51 | 9,819 | $34.5K | 7,395,185 | |
NMRA | BERNS PAUL L | — | Feb 17, 2026 | Proposed Sale | $3.51 | 9,819 | $34.5K | — | |
NMRA | BERNS PAUL L | — | Feb 18, 2025 | Proposed Sale | $1.69 | 13,871 | $23.5K | — |